Novel SERM Cut Postmenopausal Fractures : Lasofoxifene also reduced cancer and heart risks, but one expert says it's no better than existing agents.

The PEARL study was funded by Pfizer, manufacturer of lasofoxifene. Pfizer submitted a new drug application to the Food and Drug Administration in 2007, and in 2008 an advisory panel voted 9–3 that the benefits of the SERM outweighed this risk in postmenopausal women with osteoporosis. The FDA has not yet issued a decision.

Dr. Becker's financial disclosures are available with the text of the article at www.NEJM.org